Theranostic Translation Applications Against Viral, Metabolic Liver Diseases and Hepatic Oncogenesis: Lipoprotein and Apolipoproteins at a Crossroad
Trial Snapshot
- Phase
- Not Applicable
- Sponsor
- Enrollment
- 440
- Locations
- 1
- Primary Endpoint
- Theranostic Translation Applications Against Viral, Metabolic Liver Diseases and Hepatic Oncogenesis: Lipoprotein and Apolipoproteins at a Crossroad
Study Overview
Brief Summary
Theranostic translation applications against viral, metabolic liver diseases and hepatic oncogenesis: lipoprotein and apolipoproteins at a crossroad
Detailed Description
An intimate link between microbial infections, metabolic changes and oncogenesis has been drawn attentions increasingly, indicating a crossroad leading to pathogenesis and disease progression. Globally the burden of hepatitis B and C virus infections is 450 and 185 millions, respectively and chronic hepatitis disease causes a high risk of liver cirrhosis, hepatocellular carcinoma and metabolic disorders
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Retrospective
Eligibility Criteria
- Ages
- 20 Years to 70 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •above 20 years
- •nonalcoholic fatty liver disease
- •Non-Alcoholic Steatohepatitis
Exclusion Criteria
- •alcohonic hepatitis
- •Autoimmune liver disease
- •HIV postive
Outcomes
Primary Outcomes
Theranostic Translation Applications Against Viral, Metabolic Liver Diseases and Hepatic Oncogenesis: Lipoprotein and Apolipoproteins at a Crossroad
Time Frame: 2years
Study the interplay between hepatitis C virus (HCV) and lipid metabolism(the HCV infection affects host lipid homeostasis, regarding transportation, synthesis, and catabolism.)
Secondary Outcomes
No secondary outcomes reported
Investigators
Chun-Hsiang Wang
Tainan Municipal Hospital
Tainan Municipal Hospital